Diatomaceous earth/zinc oxide micro-composite assisted antibiotics in fungal therapy.
Antibiotic efficacy
Antifungal therapy
Biocompatibility
Persistent therapy
Synergistic effect
Journal
Nano convergence
ISSN: 2196-5404
Titre abrégé: Nano Converg
Pays: England
ID NLM: 101695675
Informations de publication
Date de publication:
25 Oct 2021
25 Oct 2021
Historique:
received:
12
07
2021
accepted:
05
10
2021
entrez:
25
10
2021
pubmed:
26
10
2021
medline:
26
10
2021
Statut:
epublish
Résumé
As the second wave of COVID-19 hits South Asia, an increasing deadly complication 'fungal infections (such as Mycosis, Candida and Aspergillus) outbreak' has been raised concern about the insufficient technologies and medicals for its diagnosis and therapy. Biosilica based nano-therapy can be used for therapeutic efficacy, yet their direct role as antibiotic agent with biocompatibility and stability remains unclear. Here, we report that a diatomaceous earth (DE) framework semiconductor composite conjugated DE and in-house synthesized zinc oxide (DE-ZnO), as an antibiotic agent for the enhancement of antibiotic efficacy and persistence. We found that the DE-ZnO composite had enhanced antibiotic activity against fungi (A. fumigatus) and Gram-negative bacteria (E. coli, S. enterica). The DE-ZnO composite provides enhancing large surface areas for enhancement of target pathogen binding affinity, as well as produces active ions including reactive oxygen species and metal ion for breaking the cellular network of fungi and Gram-negative bacteria. Additionally, the toxicity of DE-ZnO with 3 time less amount of dosage is 6 times lower than the commercial SiO
Identifiants
pubmed: 34694514
doi: 10.1186/s40580-021-00283-6
pii: 10.1186/s40580-021-00283-6
pmc: PMC8542915
doi:
Types de publication
Journal Article
Langues
eng
Pagination
32Informations de copyright
© 2021. The Author(s).
Références
ACS Nano. 2020 Apr 28;14(4):4755-4766
pubmed: 32207961
Mycoses. 2021 May 20;:
pubmed: 34013523
Nano Converg. 2020 Apr 23;7(1):14
pubmed: 32328852
Nat Commun. 2019 Apr 10;10(1):1669
pubmed: 30971696
Int J Biol Macromol. 2018 Mar;108:1281-1288
pubmed: 29129632
Sci Total Environ. 2020 Jun 15;721:137625
pubmed: 32169638
Nat Commun. 2018 Aug 6;9(1):3098
pubmed: 30082817
Theranostics. 2021 Apr 19;11(13):6334-6354
pubmed: 33995661
Med Mycol. 2019 Apr 1;57(Supplement_2):S161-S167
pubmed: 30816968
Nano Converg. 2018;5(1):10
pubmed: 29682442
Adv Mater. 2019 Feb;31(7):e1806024
pubmed: 30589118
BMC Cancer. 2017 Oct 16;17(1):684
pubmed: 29037232
Nat Commun. 2020 Jan 8;11(1):127
pubmed: 31913284
Adv Mater. 2018 May;30(19):e1704289
pubmed: 29178521
Chem Rev. 2019 Apr 24;119(8):4881-4985
pubmed: 30973011
Lancet Infect Dis. 2021 Jun;21(6):e149-e162
pubmed: 33333012
Nano Converg. 2016;3(1):34
pubmed: 28191444
Eur J Pharm Biopharm. 2017 Jun;115:65-72
pubmed: 28223260
Cancer Cell. 2010 Apr 13;17(4):388-99
pubmed: 20385363
Nano Converg. 2016;3(1):26
pubmed: 28191436
Adv Sci (Weinh). 2019 Dec 05;7(1):1901872
pubmed: 31921562
J Microbiol Immunol Infect. 2021 Feb;54(1):46-53
pubmed: 33012653
Nat Commun. 2020 Jan 22;11(1):427
pubmed: 31969561
Nano Converg. 2021 Aug 16;8(1):24
pubmed: 34398322
Nanomedicine. 2013 Nov;9(8):1328-35
pubmed: 23727099
Microbiol Spectr. 2021 Sep 3;9(1):e0001021
pubmed: 34106569
Nano Converg. 2017;4(1):33
pubmed: 29214127
Chem Soc Rev. 2020 Apr 21;49(8):2426-2480
pubmed: 32140691
Lancet Infect Dis. 2019 Dec;19(12):e405-e421
pubmed: 31699664
Ecotoxicology. 2018 Apr;27(3):352-359
pubmed: 29411207
Nat Commun. 2018 Nov 29;9(1):5072
pubmed: 30498236
J Clin Microbiol. 2020 Dec 17;59(1):
pubmed: 33087440
Small. 2020 Sep;16(36):e2000980
pubmed: 32338444
ACS Appl Mater Interfaces. 2021 Sep 1;13(34):40401-40414
pubmed: 34405670
Adv Mater. 2017 Dec;29(46):
pubmed: 29068546